Alnylam Pharmaceuticals Inc’s recent filing unveils that its Chief Executive Officer Greenstreet Yvonne unloaded Company’s shares for reported $9.63 million on May 30 ’25. In the deal valued at $304.39 per share,31,640 shares were sold. As a result of this transaction, Greenstreet Yvonne now holds 48,948 shares worth roughly $15.11 million.
Then, Greenstreet Yvonne sold 19,297 shares, generating $5,904,882 in total proceeds. Upon selling the shares at $306.00, the Chief Executive Officer now owns 48,948 shares.
Before that, Greenstreet Yvonne bought 19,297 shares. Alnylam Pharmaceuticals Inc shares valued at $5,848,824 were divested by the Officer at a price of $303.10 per share.
Redburn Atlantic initiated its Alnylam Pharmaceuticals Inc [ALNY] rating to a Buy in a research note published on March 31, 2025; the price target was $353. A number of analysts have revised their coverage, including JP Morgan’s analysts, who increased its forecast for the stock in late March from “a Neutral” to “an Overweight”. Wolfe Research also remained covering ALNY and has decreased its forecast on November 12, 2024 with a “an Underperform” recommendation from previously “Peer perform” rating. Scotiabank started covering the stock on October 16, 2024. It rated ALNY as “a Sector outperform”.
Price Performance Review of ALNY
On Monday, Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] saw its stock jump 0.26% to $308.78. Over the last five days, the stock has gained 1.57%. Alnylam Pharmaceuticals Inc shares have risen nearly 31.22% since the year began. Nevertheless, the stocks have risen 94.15% over the past one year. While a 52-week high of $310.22 was reached on 06/06/25, a 52-week low of $152.30 was recorded on 04/09/25.
Levels Of Support And Resistance For ALNY Stock
The 24-hour chart illustrates a support level at 304.19, which if violated will result in even more drops to 299.60. On the upside, there is a resistance level at 311.50. A further resistance level may holdings at 314.22.
